In vitro activity of beta-lactams and quinolones against AmpC beta-lactamase-producing Escherichia coli. 2005

Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
Clinical Laboratory, Wakayama Rosai Hospital, 435 Koya, Wakayama, 640-8345, Japan. kyamasaki@gaia.eonet.ne.jp

We studied the antimicrobial susceptibility of AmpC beta-lactamase-producing Escherichia coli isolates collected at ten medical institutions in the Kinki area of Japan during a 6-month period (November 2002 through April 2003). Of 2845 E. coli isolates tested, 29 (1.0%) showed a minimum inhibitory concentration (MIC) for cefazolin of more than 8 microg/ml and were three-dimensional extract test positive. In standard inoculum susceptibility tests against these 29 strains, the MIC90s for the four carbapenems tested ranged from 0.06 microg/ml to 0.5 microg/ml, and these compounds were more active than the other beta-lactams, with meropenem being the most active. The MIC90s for beta-lactams, except carbapenems, ranged from 4 microg/ml to 32 microg/ml, with cefepime being the most active. In high inoculum susceptibility tests against these strains, the MIC90s for the four carbapenems and cefepime were 8 microg/ml or less, and these compounds were more active than other beta-lactams. The MIC90s for beta-lactams, except carbapenems and cefepime, were 32 microg/ml or more. The MIC90s for the five quinolones tested ranged from 4 microg/ml to 16 microg/ml, and the order of increasing susceptibility was ciprofloxacin > levofloxacin, gatifloxacin and pazufloxacin > prulifloxacin.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002437 Cefazolin A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Cephazolin,Ancef,Cefamedin,Cefamezine,Cefazolin Sodium,Cephamezine,Cephazolin Sodium,Gramaxin,Kefzol,Sodium Cephazolin,Totacef,Cephazolin, Sodium,Sodium, Cefazolin,Sodium, Cephazolin
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D006761 Hospitals Institutions with an organized medical staff which provide medical care to patients. Hospital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial

Related Publications

Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
July 2006, The Journal of antimicrobial chemotherapy,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
April 2006, The Journal of antimicrobial chemotherapy,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
January 2016, BioMed research international,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
March 2007, Emerging infectious diseases,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
October 2004, International journal of antimicrobial agents,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
February 2005, Journal of chemotherapy (Florence, Italy),
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
November 1989, The Journal of antimicrobial chemotherapy,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
February 2018, Medicine,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
October 2007, Journal of basic microbiology,
Katsutoshi Yamasaki, and Masaru Komatsu, and Koichi Shimakawa, and Kaori Satoh, and Hisaaki Nishio, and Noriyuki Sueyoshi, and Masahiro Toyokawa, and Masako Sakamoto, and Takeshi Higuchi, and Yasunao Wada, and Tomomi Kofuku, and Tamaki Orita, and Tomonari Yamashita, and Shohiro Kinoshita, and Masanori Aihara
January 2010, Enfermedades infecciosas y microbiologia clinica,
Copied contents to your clipboard!